CVGRX Performance — Calamos Growth Fund, Class A
Data updated: 2026-09-29
CVGRX returned +5.68% year to date and +12.01% over one year to Jul 2026. Annualised returns are +19.56% over 3 years and +9.78% over 5 years. The fund beat its US Large Growth category average: $100 invested three years ago grew to $171, against $166 for the category, and to $112 over one year, against $111. Volatility over the past three years was 17.47% a year. In the 12 months to Jul 2026 the fund lost a net $25.6M, and assets reached $1.71B.
CVGRX Growth of $100
What $100 invested in Calamos Growth Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Growth category average over the same months.
| Period | CVGRX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $112 | $111 |
| 3 years (Aug 2023 – Jul 2026) | $171 | $166 |
| 5 years (Aug 2021 – Jul 2026) | $159 | $158 |
| Since data start (Aug 2019 – Jul 2026) | $256 | $261 |
CVGRX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +5.68% |
| 1 year | +12.01% |
| 3 years (annualised) | +19.56% |
| 5 years (annualised) | +9.78% |
CVGRX Annual Returns
Calendar-year total returns of Calamos Growth Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +5.68% |
| 2025 | +16.13% |
| 2024 | +32.27% |
| 2023 | +37.55% |
| 2022 | −33.34% |
| 2021 | +23.27% |
| 2020 | +32.93% |
| 2019 (Aug–Dec) | +5.08% |
CVGRX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.7% | −4.1% | −5.5% | +15.0% | +6.7% | −2.2% | −2.1% | — | — | — | — | — |
| 2025 | +2.7% | −4.1% | −9.3% | +1.8% | +9.4% | +7.1% | +2.8% | +1.1% | +3.0% | +3.5% | −1.3% | −0.5% |
| 2024 | +3.0% | +6.9% | +2.1% | −3.8% | +5.5% | +6.2% | −2.4% | +2.4% | +2.5% | −0.1% | +6.9% | −0.2% |
| 2023 | +7.9% | −1.7% | +6.1% | +1.4% | +4.7% | +6.7% | +2.6% | −1.2% | −5.8% | −1.6% | +10.5% | +4.0% |
| 2022 | −10.0% | −3.8% | +3.6% | −13.2% | −3.6% | −8.0% | +10.8% | −4.5% | −9.6% | +5.1% | +4.1% | −7.8% |
| 2021 | −0.2% | +3.2% | 0.0% | +5.9% | −1.9% | +5.7% | +1.8% | +3.7% | −5.0% | +8.6% | −0.7% | +0.7% |
| 2020 | +2.2% | −7.2% | −14.2% | +13.9% | +8.7% | +4.5% | +5.0% | +9.4% | −4.4% | −2.9% | +12.7% | +5.1% |
| 2019 | — | — | — | — | — | — | — | −1.7% | −0.6% | +1.4% | +4.7% | +1.4% |
CVGRX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 17.47%
- 3-year Sharpe ratio: 0.86 (vs 4.5% risk-free rate)
- Best month: +15.00% (Apr 2026)
- Worst month: −9.29% (Mar 2025)
CVGRX Fund Flows
Monthly money in and out of Calamos Growth Fund, from SEC Form N-PORT.
- 12-month net flow: −$25.6M
- 12-month gross sales (incl. reinvestments): $174.4M
- Sales ÷ redemptions: 0.87×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $7.9M | $17.8M | −$9.9M |
| Jun 2026 | $6.7M | $18.8M | −$12.1M |
| May 2026 | $1.7M | $13.2M | −$11.5M |
| Apr 2026 | $3.1M | $18.8M | −$15.7M |
| Mar 2026 | $2.3M | $13.5M | −$11.2M |
| Feb 2026 | $8.4M | $12.2M | −$3.8M |
| Jan 2026 | $3.1M | $16.1M | −$13.0M |
| Dec 2025 | $128.8M | $24.0M | $104.9M |
| Nov 2025 | $3.8M | $17.6M | −$13.8M |
| Oct 2025 | $2.3M | $17.6M | −$15.3M |
| Sep 2025 | $4.2M | $18.5M | −$14.3M |
| Aug 2025 | $2.2M | $12.0M | −$9.8M |
CVGRX Assets Under Management
Net assets of Calamos Growth Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $1.71B |
| 2026-04-30 | $1.71B |
| 2026-01-31 | $1.67B |
| 2025-10-31 | $1.76B |
| 2025-07-31 | $1.67B |
| 2025-04-30 | $1.42B |
| 2025-01-31 | $1.64B |
| 2024-10-31 | $1.54B |
| 2024-07-31 | $1.50B |
| 2024-04-30 | $1.40B |
| 2024-01-31 | $1.37B |
| 2023-10-31 | $1.20B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.